FDA Surrogate Endpoint Inventory May Lead To Validation Guidance
Executive Summary
FDA is creating an inventory of currently used surrogate endpoints that will be used to help the agency formulate a disease-oriented validation pathway
You may also be interested in...
Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk
Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21
Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk
Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21
FDA’s Progress On Biomarkers: Two Steps Forward, One Step Back?
FDA is moving ahead with its biomarker validation efforts with the establishment of a consortium with the Pharmaceutical Research & Manufacturers of America and NIH, but the agency has halted an internal biomarker survey in favor of a broader inventory of endpoints